ABBV · News · 20260829N
Revenue Performance and Mix
AbbVie Inc. · 2026-08-29 · Importance 32 · Surprise 6 · In source text
AbbVie reported second-quarter 2026 revenue of $16.99 billion, exceeding consensus estimates. Adjusted EPS was $3.65, also above consensus, with both revenue and adjusted EPS showing significant year-over-year growth. Skyrizi remained the principal growth driver for AbbVie’s Immunology segment.
Key facts
- AbbVie reported revenue of $16.99 billion and EPS of $3.65, both exceeding consensus estimates for Q2 2026. source
- Q2 2026 revenue: $16.99 billion. source
- Q2 2026 EPS: $3.65. source
- AbbVie Inc. stock is trading near $256. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | AbbVie reported revenue of $16.99 billion and EPS of $3.65, both exceeding consensus estimates for Q2 2026. |
| net_income | positive | realized | — | AbbVie reported revenue of $16.99 billion and EPS of $3.65, both exceeding consensus estimates for Q2 2026. |